葛兰素史克在研肝病创新疗法拟纳入突破性治疗品种;博锐创合与诺华达成授权合作,交易额最高达60亿元 | 医药早参

每日经济新闻
Sep 23

|2026年9月23日星期三|  NO.1葛兰素史克在研肝病创新疗法拟纳入突破性治疗品种  中国国家药监局药品审评中心官网公示显示,葛兰素史克申报的注射用efimosfermin alfa拟纳入突破性治疗品种,拟用于治疗成人代谢相关脂肪性肝炎。公开资料显示,这是一款在研、每月一次注射给药的成纤维细胞生长因子21(FGF21)类似物,可调控关键代谢通路,减少肝脏脂肪沉积、改善肝脏炎症,并逆转代谢相关...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10